Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Shanghai, China Clinical Trials

A listing of Shanghai, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (695) clinical trials

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome

To demonstrate that the treatment effect in refractory nephrotic syndrome of MZR is non-inferior to that of standard therapy CTX through analyzing overall remission rate after treatment.

Phase

0.0 miles

Learn More »

The objective of this study is to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy.

Phase

0.0 miles

Learn More »

Test Albuvirtide in Experienced Patients

This is a 48-week, randomized, controlled, open-label, multicenter study of the safety and efficacy of albuvirtide plus lopinavir-ritonavir in HIV-1 infected adults who are failing their first antiretroviral regimen and have HIV-1 RNA levels >= 1000 copies/mL at screening. Subjects meeting inclusion criteria are randomized in a 1:1 ratio to ...

Phase

0.0 miles

Learn More »

Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature

This was a multicenter, randomized phase II study, half of participants will receive the high dose, while the other half will receive the low dose.

Phase

0.0 miles

Learn More »

Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)

This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad of population of children.

Phase

0.0 miles

Learn More »

Fatty Liver Disease Collaborative Research in China

This is a multicenter, prospective and open-enrollment epidemiologic study. All the patients with liver biopsy-proven macrovesicular steatosis (>5%) will be enrolled in the baseline cross-sectional analysis. Those who are either diagnosed as NAFLD or ALD, if meeting all the inclusion and exclusion criteria, will be enrolled in the following cohort ...

Phase N/A

0.0 miles

Learn More »

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Evaluating efficacy & safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age with idiopathic generalized epilepsy currently taking 1 to 3 antiepileptic drugs. Maximum duration of study drug administration is 28 weeks. Eligible subjects may ...

Phase

0.0 miles

Learn More »

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

The purpose of this study is to compare the rate of disease free survival (DFS) and distant disease free survival (DDFS) at 5 years in postmenopausal women with hormone receptor and lymph node positive breast cancer randomized between anastrozole/letrozole 5 years and anastrozole/letrozole 2-3 years switching to exemestane 3-2 years.

Phase

0.0 miles

Learn More »

Targin for Non-cancer Pain

To determine the improvement in symptoms of constipation in subjects receiving treatment with oxycodone/naloxone prolonged release tablets (OXN) compared to oxycodone prolonged release tablets (OXY) based on the Bowel Function Index (BFI)

Phase

0.0 miles

Learn More »

INternational ORthopaedic MUlticenter Study in Fracture Care (INORMUS)

Number of Participants: 40,000 Primary Research Objectives: To determine among adult individuals admitted to hospital with musculoskeletal trauma (e.g. fractures or dislocations): The incidence of major complications (mortality, re-operation and infection) as a composite outcome and as individual components within 30 days post-hospital admission. The factors (system and patient variables) ...

Phase N/A

0.0 miles

Learn More »